tegrate infor m ation fro m their for m al education ， with experience gained in practice ， and findings fro m ne w research studies to provide the best care to their patients ． T hese sources of kno wledge all contribute to w hat is for m ally ter m ed ＂ evidence＂ ， and serve to infor m and im prove patient care ． Al though clinicians m ay believe that E B M is overly co m plex ， at its core E B M is sim ply an atte m pt to learn fro m the past and apply w hat w e already kno w to im prove patient care ． With this in mind ， E B M is accessible to everyone involved in healthcare and has recently burgeoned as clinicians ， researchers ， policy m akers ，and patients e m brace this concept as an im portant tool in decision m aking ． An under standing of the basic principles of E B M is crucial in order to critically appraise clinical studies ．
T Y PE S O F C LINIC A L S T U DIE S
H ealth research is a broad field and there are several different types of studies being conducted and reported in journals and else w here ． Clinical studies （ also called clinical trials ， though this is so m etim es used to refer only to rando mized con trolled trials -R C Ts） m ay be broadly defined as re search to assess the efficacy and／or safety of a treat m ent in hu m an participants ［ ６ ］ ． Within the field of clinical studies are several co m m on study de signs ． Identifying the type of clinical study being reported in an article is the first co m ponent of critical appraisal ． So m e of the m ost co m m only conducted and reported clinical study designs are ： （ １ ） descriptive （ case report／case series ） ； （２） cohort （ retrospective／prospective） ； （ ３ ） con trolled （ nonrando mized ， quasirando mized ， and rando mized） ． Basic features of these study designs are su m m a rized in Table １ ， w hich will help readers recognize and evaluate reports of these study designs in the literature ． D eter mining the type of clinical study being reported can be challenging and the study design reported by authors m ay not alw ays be ade quately described within their research m ethodolo gy ． Further m ore ， designs m ay overlap and so m e design aspects of studies m ay share properties with other study designs ． For exa m ple ， a study presen ting itself as a prospective cohort that fails to de scribe the study population ，inclusion／exclusion cri teria ， and study tim eline ， could therefore be inter preted sim ply as a case series ． T he final decision as to the type of study being reported in a journal arti cle m ay therefore be based on overall im pressions rather than the presence or absence of specific cri teria co m m on to each study design ． A general rule to consider is that there should be little a m biguity for a reader to deter mine the study design in a w ell conducted and reported clinical study ． Further m ore ，it is im portant to note that the study design should be described in a reproducible m anner so that another investigator could apply the sa m e m ethods and obtain similar results if applied to an equivalent population ．
S T R E N G T H S A N D LI M IT A TIO N S O F S T U D Y D ESIG N S
T here are inherent strengths and w eaknesses to each study design ． For exa m ple ， a case report pro vides detailed infor m ation on a single patient that m ay be representative of a ne w condition and／or treat m ent approach ． W hen several patients are in volved this is considered a case series ．It is difficult to generalize results to other patients based on such limited observations ， but these studies can alert cli nicians to ne w disease entities or m ethods of treat m ent ． Cohort studies build on case reports／series by defining a broader patient population to increase the generalizability of their results ． T hey are an excellent starting point for assessing study m ethods to be used in future studies ， gathering preliminary evidence of efficacy to justify further studies ， and providing data that can be used for deter mining sa m ple size in R C Ts ． Although the focus here is on clinical studies ， cohort studies are also used in epide miological studies to observe the potential health effects of exposure to various substances or pheno m ena over tim e （e ．g ．lung cancer and asbes tos） ． H o w ever ， w hen exa mining a particular inter vention ， it is difficult to attribute the results of a cohort study without rando mization ，blinding ，and a control group ． Controlled trials are often cited as the gold standard for deter mining the efficacy of an intervention ， but m ethods developed for phar m a ceutical intervention studies m ay not alw ays be suitable for trials of C A M interventions ． For exa m ple ， the use of W estern m edicine diagnoses and standardized treatm ent regim ens for all participants m ay not reflect C A M practice
A single clinical study can rarely be thought of as definitive and m ust be taken in the broader context of all available evidence for a particular interven tion ． Gathering research into the efficacy of an in tervention typically requires m ultiple studies con ducted over several years by different investigators and study sites ． As each clinical study is published ， others m ay be conducted by using slightly different study designs or m ethods to answ er different re search questions ． W hen m ultiple studies have been conducted on the sa m e topic ， they ， as a w hole ， constitute the body of evidence for that interven tion ． 5 ．1 Bias and confounding W ithin that body of healthcare literature is a hierarchy of evidence that has been established based on the strengths and limitations inherent to specific study designs as m entioned above （see Fig ure １） ［ ９ ］ ． T his hierarchy of evidence also indicates a study design＇s susceptibility to bias and confoun ding ， w hich are tw o im portant concepts in E B M ． Bias is the distortion of study data ， w hereas con founding is the inability to distinguish the separate im pacts of m ultiple variables on a single out co m e ［ １ ０ ］ ． E xa m ples of bias include selection bias （i ．e ． participants not representative of population ） ， m easure m ent bias （i ．e ． outco m e m easure not accu rate） ， and responder bias （i ．e ． participants co m pleting study differ fro m others） ． A n exa m ple of confounding could be a clinical study of acupuncture for back pain w hereby participants in both the in tervention and control groups report im prove m ent ． H o w ever ，if both groups had to first lie do w n on a co mfortable table for ３０ minutes in a quiet roo m ， the im prove m ent in pain could be attributed to
reducing stress rather than the intervention ． Clini cians reading clinical studies should therefore ask the mselves w hether a study＇s results could have been influenced by bias and confounding as part of the critical appraisal process ． In addition to the ３ co m m on prim ary （i ．e ． pa tient level data） clinical study designs described in Table １ ，other nonexperim ental study designs ，and secondary （i ．e ． study level data） study designs are ranked within this hierarchy of evidence and are briefly described belo w ． ． W hen readers of the health literature discover such discrepancies ， they should first identify the study design to place it within the hierarchy of evidence ． T he reader should then evaluate the study＇s validity and m ethodological quality ． Since R C T s are one of the m ost co m m on and im portant clinical study designs ， m ethods for critically appraising R C Ts are described belo w ． 6 ．2 R ando mized controlled trial Clinicians will encounter nu m erous R C Ts as they read scientific health journals ． Although such designs account for only about ２ ％ of the total healthcare literature found in M edline ， the nu m ber of published R C Ts is gro wing at １１ ％ annually ［ １ ６ ］ ． R esults fro m R C Ts are often touted by proponents or opponents of a particular intervention as ＂defini tive proof＂ of efficacy ，or lack thereof ， of an inter vention ． H o w ever ， the discerning reader will first appraise the m ethodology of a particular study before considering its im plications ． T his is a crucial step since e m pirical evidence suggests that bias ex ists in R C T s with poor m ethodological quality and／ or R C Ts that do not fully report their m ethods
T his latter point is im portant since ，in m ost cases ， the only w ay for readers to judge ho w the R C T w as conducted is by exa mining its report ． Surveys of the current literature indicate that although there is definite im prove m ent in ho w R C Ts are reported ， m any of the m are still not optim ally reported 
DI S C U SSI O N ２ ０
Interpretatio n D escrib e th e interpretatio n of th e results an d take into accou nt a n y trial h y poth eses ． R ep ort li mitations of the trial su ch as sources of bias an d m ultiple a nalyses ， w hic h increases y o ur chan ces of rejectin g th e n ull hy p othesis w h en it w as in fact true （i ．e ．， y ou find th at a differe nce bet w een the interventions e xist w h en they w ere in fact the sa m e ． T his is oth er w ise k no w n as a ＂typ e １ ＂ error） ． ２ １ Ge neralizability G eneralizability relates to th e de gree for w hich th e trial res ults ca n be inferred to a larger pop ulatio n b e yo n d th e trial participa nts ． A noth er term for g eneralizability is e xtern al validity ． Describe th e e xtent of rating scales are not sufficient to conduct critical appraisal of a clinical study ， and should sim ply be vie w ed as one of the tools available to help clini cians deter mine w hether the results of a study are valid ． B eing a w are of the limitations of m ethodolog ical quality rating scales will help clinicians deter mine their role in critical appraisal ，if any ．
IS S U E S S PE CIFIC T O H E R B A L M E DICIN E
T he research m ethods co m m only used in clinical studies such as using an inert sugar pill as a placebo or blinding the clinician ， outco m e assessor and pa tient w ere originally developed by researchers to assess the efficacy of oral phar m aceuticals ． Al though these m ethods are valid in that context ，it is difficult to ascertain w hether they can （or should） be used in research involving nonphar m aceutical interventions such as C hinese herbal m edicine （ C H M ） ， w hich is based on entirely different foun dations and principles ． T hese differences m ust be considered w hen appraising clinical studies ． So m e of the m ethodological quality issues that are unique to clinical studies involving C H M ，for exa m ple ，in clude ： defining the targeted population and disease of interest ； ad ministering a standardized interven tion to all participants ； and quality control of the intervention ． E ach is briefly discussed belo w to provide clini cians with another perspective w hen perfor ming critical appraisal of the quality of clinical study reports they read related to C H M ． co m ponents could then be altered by a clinician to address specific concerns according to a patient' s overall health ． T his individual approach to health practice is one of the aspects that distinguish a tra ditional healing syste m （such as C H M ） apart fro m W estern m edicine ， w hich often prescribes specific re m edies based on explicit diagnoses ， regardless of overall health ． T his distinction raises the issue of w hether R C Ts in w hich a standard intervention is given to all participants is an accurate representa tion of C H M practice ． Clinicians should therefore consider w hether the restrictions im posed on a clin ical study because of its research nature is reflective of their usual approach to a particular patient w hen interpreting study results ． 8 ．3 Q uality control of herbal m edicine T his issue is rarely discussed in reports of trial m ethods yet it is crucial to the validity of the study's results
． U nlike W estern phar m aceutical products that are standardized by adhering to strict quality control m easures for m anufacturing and batch release testing such as the G ood M anufactur ing Practices （ G M P） ， C H M products rarely under go quality control ． T he prim ary reasons for execu ting quality control of C H M products include consis tency and safety ．In order to assess the efficacy of a specific product in a clinical study ， all participants should be given exactly the sa m e intervention in ter m s of product identity ， purity ， dosage ，for m ula tion ， etc ． T his should be acco m plished by testing all stages of production ， fro m the ra w m aterial to the final products ， and could also extend to other aspects of production such as the species and subspecies of plant used ， the location of gro wth ， m ethod of harvest ，transportation ， and processing ， etc ．，in order to ensure product consistency ． Products should also be tested to address safety concerns surrounding herbal products ， w hich should not be assu m ed to be innocuous ． Studies exa mining herbal products have previously reported conta mi nants such as heavy m etals ， herbicides ， pesticides ， microorganis m s ， m ycotoxins ， insects ， phar m aceu ticals ， and other undeclared herbal constituents 
